Cartesian Therapeutics(RNAC)
FREDERICK, MDBiotechnology
Focus: Cartesian Therapeutics is a public biotech company developing mRNA-engineered cell therapies, operating at a very small scale with 1-50 employees focused on autologous cell therapy programs.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Employees
1-50
Open Jobs
8+8 this month
Growing — net +8 jobs in 30d
10 jobs added vs 2 removed. Steady team buildout.
Should You Work at Cartesian Therapeutics?
AI assessmentA high-risk, high-reward opportunity for entrepreneurial scientists seeking early-stage exposure to cutting-edge cell therapy, but unsuitable for those prioritizing stability, mentorship, or near-term career advancement.
Why Work Here
- Early-stage platform company with novel mRNA-engineered cell therapy technology addressing multiple serious indications across autoimmune, oncology, and inflammatory disease
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Growing
Jobs increasing
Pipeline & Clinical Trials
Descartes-25
Multiple MyelomaClinical Trials (1)
NCT05113342Descartes-25 in Relapsed/Refractory Multiple Myeloma
Phase 1Help build intelligence for Cartesian Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.